{"preliminary_commentary":{"by_channel":{"x_thread":7},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"DEWI","nct_id":"NCT06059495","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dewi-nct06059495. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DEWI","arms":[{"description":"After inclusion patients will receive dostarlimab at 500 mg q3w (± 2-3 days) for 4 cycles (C1-C4). Then, an adaptive treatment strategy will be determined based on clinical assessment of the patient.","label":"Dostarlimab-based treatment","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-09-01","type":"ESTIMATED"},"conditions":["Adenocarcinoma - GEJ","Gastric Adenocarcinoma"],"enrollment":{"count":89,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Dostarlimab","otherNames":["Jemperli"],"type":"DRUG"}],"last_update":"2026-08-26","lead_sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","official_title":"Watch-and-wait Strategy to Initiate Dostarlimab-based Immunotherapy in Localized Deficient Mismatch Repair (dMMR) and/or Microsatellite Instability High (MSI-H) oEso-gastric Junction and Gastric Adenocarcinoma: An Open-label GERCOR Phase II Study","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-09-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Clinical complete response (cCR)","timeFrame":"At 1 year from the start of treatment with dostarlimab."}],"references":[],"start_date":{"date":"2024-01-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study","url":"https://clinicaltrials.gov/study/NCT06059495"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dewi-nct06059495"}